查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949544

DNA診斷市場－全球產業規模、佔有率、趨勢、機會及預測（按技術、應用、地區和競爭格局分類，2021-2031年）

DNA Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 DNA 診斷市場預計將從 2025 年的 128.6 億美元成長到 2031 年的 180.1 億美元，複合年成長率為 5.77%。

DNA診斷是一種能夠精確檢測遺傳物質，從而發現特定突變、染色體異常或與遺傳性感染疾病相關的生物標記的技術。推動該市場發展的關鍵因素是全球慢性病和感染疾病發病率的上升，這需要快速且準確的檢測能力；以及醫療保健策略向個人化醫療的轉變。世界衛生組織（世衛組織）在2024年的報告中強調了這項迫切需求：2023年全球約有820萬例新增結核病病例，這是自監測開始以來年度新增病例數最高的一年。

市場概覽
預測期 2027-2031
市場規模：2025年 128.6億美元
市場規模：2031年 180.1億美元
複合年成長率：2026-2031年 5.77%
成長最快的細分市場 基於PCR的診斷
最大的市場 北美洲

然而，由於法規環境複雜多變，進入門檻高，市場成長面臨許多挑戰。檢查室自研檢測的嚴格監管為製造商帶來巨大的不確定性和更高的合規成本，可能延緩創新診斷檢測的上市。此外，不同司法管轄區報銷政策的不一致往往加劇了這些監管壓力，限制了患者獲得先進基因檢測的機會，並限制了相關人員的收入前景。

市場促進因素

次世代定序技術的快速發展正從根本上改變DNA診斷領域，顯著提升了檢測通量並縮短了結果交付時間。高通量定序平台的引入使檢查室能夠以極快的速度和極低的成本處理基因檢體，從而推動了其在臨床環境中的廣泛應用。例如，Illumina公司於2024年2月發布的「2023會計年度第四季及全年財務業績」報告顯示，該會計年度共交付了352台NovaSeq X定序儀，充分展現了尖端定序基礎設施在市場上的強勁需求。這項技術的廣泛應用實現了全面的基因組分析，使得以往難以識別的複雜基因突變得以檢測，加速了基因組學在日常醫療保健中的應用。

同時，由於精準醫療和早期疾病檢測的重要性，診斷技術在癌症診斷領域的廣泛應用成為推動該領域的主要動力。隨著全球癌症負擔的加重，醫療服務提供者越來越依賴液態生物檢體和基因組檢測來制定個人化的治療方案。世界衛生組織（WHO）下屬的國際癌症研究機構（IARC）估計，2022年全球新增癌症病例約2,000萬例，凸顯了診斷需求的巨大規模。因此，專科醫療機構對特異性檢測的需求激增。例如，Guardant Health在其2024年2月發布的「2023年第四季及全年業績報告」中指出，其臨床檢測量增加了39%，全年為客戶提供了172,900次檢測。

市場挑戰

複雜且不斷變化的監管環境對全球DNA診斷市場的發展構成重大障礙。尤其針對檢查室自建檢測（LDT）和體外診斷試劑的嚴格監管，顯著提高了臨床檢查室和生產商的進入門檻。這些日益嚴格的監管要求需要大量的檢驗程序，迫使企業將大量資源投入合規而非創新。這項變更直接增加了推出新檢測方法所需的資金，延長了研發週期，有效延緩了先進診斷工具的商業化進程，並限制了患者獲得必要的基因檢測的機會。

這些合規障礙帶來的財務負擔龐大且可量化。根據歐洲醫療技術協會 (MedTech Europe) 2024 年的報告，在新體外診斷醫療設備法規 (IVDR) 下，診斷設備製造商的認證和維修成本將比先前的指令增加高達 100%。營運成本的急劇上升會抑制企業對新檢測技術研發的投資，迫使企業重新評估其策略重點，最終阻礙產業的擴張潛力和收入成長。

市場趨勢

實驗室正日益將人工智慧 (AI) 和機器學習演算法融入其生物資訊學工作流程，以實現數據解讀自動化、提高診斷準確性並管理定序產生的大量資料集。這種整合消除了人工突變分析的關鍵瓶頸，從而能夠提供可擴展的臨床決策支援並快速識別複雜的遺傳疾病。 SOPHiA GENETICS 於 2025 年 3 月發布的「2024 會計年度第四季及全年」財報印證了這項廣泛應用。報告指出，2024 會計年度，使用其數據驅動平台進行的基因組分析數量達到創紀錄的 35.2 萬例，較去年同期成長 11%。

同時，技術進步正推動DNA檢測的去中心化，將複雜的分子診斷從集中式實驗室轉移到適用於診所和偏遠地區的攜帶式快速檢測設備。這項轉變已將檢測結果的周轉時間從數天大幅縮短至數分鐘，使得感染疾病和急性疾病的治療決策能夠即時做出，而無需龐大的基礎設施。生物梅里埃公司於2025年3月發布的2024年財務業績報告印證了這一市場轉變，報告指出，其SPOTFIRE快速照護現場診斷系統2024年的銷售額將達到約9500萬歐元，且年內新增安裝量為2200套。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球DNA診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依技術分類（基於PCR的診斷、次世代定序（NGS）DNA診斷、原位雜合反應診斷、基於微陣列的診斷、其他技術）
    • 依應用領域（癌症基因檢測、感染疾病DNA檢測、新生兒基因篩檢、胚胎胚胎著床前/生殖診斷、非感染疾病DNA檢測、新生兒基因篩檢、胚胎胚胎著床前/生殖診斷、非感染疾病DNA檢測）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美DNA診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章 歐洲DNA診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區DNA診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲DNA診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲DNA診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球DNA診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Illumina, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Hologic, Inc.
  • Agilent Technologies, Inc.
  • Siemens Healthineers AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25358

The Global DNA Diagnostics Market is projected to expand from USD 12.86 Billion in 2025 to USD 18.01 Billion by 2031, reflecting a CAGR of 5.77%. DNA diagnostics involve the precise examination of genetic material to detect specific mutations, chromosomal anomalies, or biomarkers linked to hereditary conditions, oncological diseases, and infectious pathologies. This market is primarily driven by the rising global incidence of chronic and infectious diseases, which necessitates rapid and accurate detection capabilities, alongside a strategic healthcare shift toward personalized medicine. Underscoring this urgent need, the World Health Organization reported in 2024 that approximately 8.2 million individuals were newly diagnosed with tuberculosis in 2023, representing the highest annual number of new cases since monitoring began.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 12.86 Billion
Market Size 2031USD 18.01 Billion
CAGR 2026-20315.77%
Fastest Growing SegmentPCR-based diagnostics
Largest MarketNorth America

However, market growth confronts significant hurdles due to a complex and shifting regulatory environment that establishes high barriers to entry. Strict oversight concerning laboratory-developed tests has created substantial uncertainty and elevated compliance costs for manufacturers, potentially delaying the launch of innovative diagnostic assays. These regulatory pressures are often exacerbated by inconsistent reimbursement policies across various jurisdictions, which limit patient access to advanced genetic testing and constrain the revenue prospects for industry stakeholders.

Market Driver

Rapid technological advancements in Next-Generation Sequencing are fundamentally transforming the DNA diagnostics sector by increasing throughput and shortening turnaround times. The deployment of high-capacity sequencing platforms allows laboratories to process genetic samples with exceptional speed and cost-effectiveness, enabling broader clinical adoption. For instance, Illumina's "Financial Results for Fourth Quarter and Fiscal Year 2023," released in February 2024, noted the shipment of 352 NovaSeq X instruments during the fiscal year, indicating robust market adoption of cutting-edge sequencing infrastructure. This technological proliferation facilitates the availability of comprehensive genomic profiling, permitting the detection of complex genetic variants that were previously challenging to identify, thereby accelerating the integration of genomics into routine medical practice.

Simultaneously, the expanding application of diagnostics in oncology is a major growth engine, driven by the critical need for precision medicine and early disease detection. With the global cancer burden intensifying, healthcare providers are increasingly relying on liquid biopsies and genomic testing to tailor treatment plans. In 2024, the World Health Organization's International Agency for Research on Cancer estimated there were approximately 20 million new cancer cases globally in 2022, highlighting the immense scale of diagnostic requirements. Consequently, specialized providers are seeing a surge in demand for cancer-specific assays; illustrating this, Guardant Health reported in its February 2024 "Fourth Quarter and Full Year 2023 Financial Results" a 39% increase in clinical testing volume, delivering 172,900 tests to customers throughout the year.

Market Challenge

The intricate and evolving regulatory landscape stands as a major impediment to the growth of the Global DNA Diagnostics Market. The enforcement of stringent oversight, particularly regarding Laboratory-Developed Tests (LDTs) and in vitro diagnostics, has created substantial barriers to entry for clinical laboratories and manufacturers. These heightened regulatory requirements necessitate exhaustive validation procedures, compelling companies to divert significant resources toward compliance rather than innovation. This shift directly increases the capital required to introduce new assays and prolongs development timelines, effectively postponing the commercialization of advanced diagnostic tools and restricting patient access to essential genetic testing.

The financial strain resulting from these compliance hurdles is both severe and quantifiable. According to MedTech Europe in 2024, the costs associated with certification and maintenance for diagnostic manufacturers under the new In Vitro Diagnostic Regulation have escalated by up to 100% compared to previous directives. This dramatic rise in operational expenditures discourages investment in new test development and forces companies to reconsider their strategic priorities, ultimately stifling the sector's potential for expansion and revenue growth.

Market Trends

Laboratories are increasingly embedding artificial intelligence and machine learning algorithms into bioinformatics workflows to automate data interpretation, enhance diagnostic accuracy, and manage the massive datasets produced by sequencing. This integration addresses the critical bottleneck of manual variant analysis, allowing for scalable clinical decision support and faster identification of complex genetic conditions. Validating this widespread adoption, SOPHiA GENETICS stated in its March 2025 "Fourth Quarter and Full Year 2024 Results" that the company conducted a record 352,000 genomic analyses using its data-driven platform in fiscal year 2024, representing an 11% year-over-year volume growth.

Technological advancements are simultaneously enabling the decentralization of DNA testing, moving complex molecular diagnostics from centralized laboratories to portable, rapid testing devices suitable for clinics and remote settings. This shift dramatically reduces turnaround times from days to minutes, facilitating immediate treatment decisions for infectious diseases and acute conditions without the need for heavy infrastructure. Underscoring this market evolution, bioMerieux reported in its "2024 Financial Results" in March 2025 that sales of the SPOTFIRE rapid point-of-care molecular system reached nearly €95 million in 2024, with the installed base expanding by 2,200 units during the year.

Key Market Players

  • Illumina, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Hologic, Inc.
  • Agilent Technologies, Inc.
  • Siemens Healthineers AG

Report Scope

In this report, the Global DNA Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Diagnostics Market, By Technology

  • PCR-based Diagnostics
  • NGS DNA Diagnosis
  • In-Situ Hybridization Diagnostics
  • Microarrays-based Diagnostics
  • Other Technologies

DNA Diagnostics Market, By Application

  • Cancer Genetics Tests
  • Infectious Diseases DNA Testing
  • Newborn Genetic Screening
  • Preimplantation & Reproductive Diagnosis
  • Non-Infectious Diseases DNA Testing
  • Newborn Genetic Screening
  • Preimplantation & Reproductive Diagnosis
  • Non-Infectious Diseases DNA Testing

DNA Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Diagnostics Market.

Available Customizations:

Global DNA Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global DNA Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (PCR-based Diagnostics, NGS DNA Diagnosis, In-Situ Hybridization Diagnostics, Microarrays-based Diagnostics, Other Technologies)
    • 5.2.2. By Application (Cancer Genetics Tests, Infectious Diseases DNA Testing, Newborn Genetic Screening, Preimplantation & Reproductive Diagnosis, Non-Infectious Diseases DNA Testing, Newborn Genetic Screening, Preimplantation & Reproductive Diagnosis, Non-Infectious Diseases DNA Testing)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America DNA Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States DNA Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada DNA Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico DNA Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application

7. Europe DNA Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany DNA Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
    • 7.3.2. France DNA Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom DNA Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy DNA Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain DNA Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Application

8. Asia Pacific DNA Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China DNA Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
    • 8.3.2. India DNA Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan DNA Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea DNA Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia DNA Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Application

9. Middle East & Africa DNA Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia DNA Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE DNA Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa DNA Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application

10. South America DNA Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil DNA Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia DNA Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina DNA Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global DNA Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Illumina, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Danaher Corporation
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. Thermo Fisher Scientific Inc.
  • 15.5. QIAGEN N.V.
  • 15.6. Abbott Laboratories
  • 15.7. Bio-Rad Laboratories, Inc.
  • 15.8. Hologic, Inc.
  • 15.9. Agilent Technologies, Inc.
  • 15.10. Siemens Healthineers AG

16. Strategic Recommendations

17. About Us & Disclaimer